FTAC Parnassuscquisition Corp. Class A (FTPA) Peer Comparison
$8.46
$-1.69
(-16.62%)
As on 03-Sep-2026 11:29EDT
Market cap
$347 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
78
P/B Ratio
1.4
Div. Yield
0 %
Edit
| FTAC Parnassuscquisition Corp. Class A (FTPA) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
347 | 5,305 | 3,392 | 778 | 449 |
Revenue ($ Mln) |
-- | 440 | 2,883 | -- | 330 |
Net Profit ($ Mln) |
9.19 | -1,435.01 | -118.30 | -134.20 | 100.20 |
Net Margin (%) |
113.07 | -325.91 | -4.10 | -- | 30.33 |
RoE (%) |
3.85 | -- | -- | -40.17 | 30.44 |
Price to Earnings |
78.00 | -- | -- | -- | 4.68 |
Price-To-Book |
1.43 | -- | 1.35 | -- | 1.31 |
Income Statement ($ Mln)
| FTAC Parnassuscquisition Corp. Class A (FTPA) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 544.48 | 2,716.30 | 32.22 | 228.69 |
|
Cost of Revenue
|
0.00 | 305.62 | 1,922.10 | 0.30 | 182.25 |
|
Gross Profit
|
-- | 238.86 | 794.20 | 31.92 | 46.44 |
|
Operating Expenses
|
1.72 | 5.21 | 682.30 | 162.14 | 56.85 |
|
Operating Profit (EBIT)
|
-1.57 | -5.21 | 111.90 | -129.92 | -10.42 |
|
Other Income
|
8.12 | -- | 0.00 | 0.86 | -18.08 |
|
Profit before Tax
|
5.47 | -32.50 | 11.20 | -131.76 | -10.42 |
|
Provision for Tax
|
-3.71 | 15.76 | 17.30 | -- | -6.70 |
|
Profit after Tax (Net Income)
|
9.19 | -32.50 | 11.10 | -131.76 | -57.92 |
|
Minority Interest
|
0.00 | -- | -- | -- | 19.55 |
|
Consolidated Profit
|
5.23 | 47.31 | -0.34 | -131.76 | -57.92 |
Liabilities ($ Mln)
| FTAC Parnassuscquisition Corp. Class A (FTPA) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
239.48 | 280.79 | -261.30 | 286.12 | 331.96 |
|
Minority Interest
|
0.00 | -- | -- | -- | 19.55 |
|
Non-Current Liabilities
|
11.37 | 61.37 | 2,376.90 | 76.52 | 158.50 |
|
Current Liabilities
|
0.51 | 4.21 | 1,887.10 | 63.02 | 324.88 |
|
Total Liabilities
|
251.13 | 346.37 | 4,325.70 | 425.65 | 2,698.57 |
Assets ($ Mln)
| FTAC Parnassuscquisition Corp. Class A (FTPA) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
251.10 | 345.03 | 3,313.70 | 156.48 | 824.54 |
|
Current Assets
|
0.27 | 1.33 | 1,012.00 | 269.18 | 1,951.91 |
|
Total Assets
|
251.13 | 346.37 | 4,325.70 | 425.65 | 2,698.57 |
|
Total Debt*
|
0.15 | 818.81 | 2,764.50 | 23.64 | 158.74 |
|
Net Current Assets
|
-0.24 | 436.27 | 1.33 | 206.16 | -- |
Cashflow ($ Mln)
| FTAC Parnassuscquisition Corp. Class A (FTPA) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-1.26 | -1.87 | -435.00 | -75.62 | -295.39 |
|
Cash Flow from Investing Activities
|
-250.00 | -423.84 | -180.70 | 92.22 | 251.38 |
|
Cash from Financing Activities
|
252.04 | 347.84 | 525.50 | 1.08 | -12.21 |
|
Net Cash Inflow / Outflow
|
-- | -- | 1.42 | 17.68 | -56.22 |
Ratios
Profitability Ratios
| FTAC Parnassuscquisition Corp. Class A (FTPA) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
0.66 | -5.10 | 0.48 | -34.71 | -11.07 |
|
ROE (%)
|
3.85 | -15.68 | -4.46 | -39.23 | -15.92 |
|
ROA (%)
|
3.65 | -11.36 | 0.28 | -27.90 | -2.09 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
113.07 | -5.97 | 0.41 | -398.26 | -27.50 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| FTAC Parnassuscquisition Corp. Class A (FTPA) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 8.03 | 0.42 | -0.50 | -0.73 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-- | -166.25 | 156.63 | -138.01 | 39.95 |
|
EPS Growth (%)
|
-- | -1.66 | 1.97 | -1.24 | 0.40 |
|
Book Value Growth (%)
|
2.23 | -- | -- | -- | -- |
Valuation Ratios
| FTAC Parnassuscquisition Corp. Class A (FTPA) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
102.65 | -106.90 | 14.22 | -19.34 | -3.15 |
|
Price / Book Value
|
0.34 | 12.37 | -0.60 | 8.91 | 0.55 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-424.10 | 70.38 | 1.59 | -17.58 | -50.19 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| FTAC Parnassuscquisition Corp. Class A (FTPA) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 2.92 | -10.58 | 0.08 | 0.48 |
|
Short term debt to equity ratio
|
0.00 | 0.37 | -3.38 | 0.07 | 0.01 |
|
Current Ratio
|
0.53 | 0.32 | 0.54 | 4.27 | 6.01 |
|
Quick Ratio
|
0.53 | -- | 0.54 | 4.26 | 7.13 |
|
Interest Coverage
|
2.77 | 0.62 | 1.16 | -49.89 | -0.12 |
Operating Efficiency Ratios
| FTAC Parnassuscquisition Corp. Class A (FTPA) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 0.31 | 25.56 | 1.28 | 470.64 |
|
Asset Turnover
|
0.00 | 1.90 | 0.68 | 0.07 | 0.08 |
|
Receivable days
|
-- | 0.94 | 77.39 | 3.29 | 1,585.02 |
|
Inventory Days
|
-- | -- | 0.00 | 1,029.23 | -1,955.46 |
|
Payable days
|
-- | 1.98 | 33.34 | 11,865.18 | 659.05 |
|
Cash Conversion Cycle
|
-- | -- | 44.05 | -10,832.66 | -1,029.48 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
